Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Opus Genetics, Inc. (IRD)

Opus Genetics Q3 net loss widens to $46.5 million; revenue falls to $1.1 million

Negative Impact 3 of 5 earnings

Opus Genetics reported a third-quarter 2026 net loss of $46.5 million, or $0.46 per share, up from $17.5 million, or $0.25 per share, a year earlier. License and collaborations revenue fell to $1.1 million from $3.1 million, while research and development expense more than doubled to $14.5 million, so shareholders face a larger loss per share with less revenue. The company said its cash of $89.0 million as of September 30, 2026, plus potential future funding under its Oberland note purchase agreement, should fund operations into 2029.

Key points

  • Net loss of $46.5 million, or $0.46 per share, versus $17.5 million, or $0.25 per share, in Q3 2025.
  • License and collaborations revenue of $1.1 million versus $3.1 million; R&D expense of $14.5 million versus $6.4 million.
  • Fair value change in instruments measured at fair value was a $28.6 million charge in the quarter.
  • Cash and cash equivalents of $89.0 million as of September 30, 2026; company expects cash to fund operations into 2029.

The filing

CompanyOpus Genetics, Inc. (IRD)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:01 AM ET
Accession number0001628280-26-072493

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:11 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.